Orphanet Journal of Rare Diseases (Nov 2016)
8th European Conference on Rare Diseases & Orphan Products (ECRD 2016)
- Michael Schlander,
- Søren Holm,
- Erik Nord,
- Jeff Richardson,
- Silvio Garattini,
- Peter Kolominsky-Rabas,
- Deborah Marshall,
- Ulf Persson,
- Maarten Postma,
- Steven Simoens,
- Oriol de Solà Morales,
- Keith Tolley,
- Mondher Toumi,
- Harry Telser,
- James R Bonham,
- Helmut Hintner,
- Anja Diem,
- Martin Laimer,
- Réjean Hébert,
- Nabarun Dasgupta,
- Carrie E. Pierce,
- Melissa Jordan,
- Barbara Bori,
- Mohanad Fors,
- Emilie Prazakova,
- Simon Day,
- Thomas J. Croce,
- Jonas Fransson,
- Philip Wood,
- Anne-Grethe Lauridsen,
- Joanne Higgs,
- Vesna Stojmirova Aleksovska,
- Christina Olsen,
- Ritchie Head,
- Antonio Asero,
- Vincenzo Papa,
- Christa van Kan,
- Loic Favennec,
- Silvana Venturella,
- Michela Salvador,
- Alan Krol,
- Stephanie J. Nielsen,
- Birthe B. Holm,
- Daniel Lewi,
- Patricia Durão,
- Heather Band,
- Andrea West,
- Marinda J. A. Hammann,
- Marije C. Effing-Boele,
- Hanka K. Dekker,
- Amy Hunter,
- Amy Simpson,
- Gumei Liu,
- Katherine Needleman,
- Debra Lewis,
- Gayatri Rao,
- Amy Simpson,
- Amy Hunter,
- Martin J. Whitaker,
- Raquel Castro
Affiliations
- Michael Schlander
- Institute for Innovation & Valuation in Health Care (Innoval-HC)
- Søren Holm
- Centre for Social Ethics and Policy, University of Manchester
- Erik Nord
- School of Pharmacy, University of Oslo
- Jeff Richardson
- Centre for Health Economics, Monash University
- Silvio Garattini
- IRCCS – Istituto di Richerche Farmacologiche Mario Negri
- Peter Kolominsky-Rabas
- Interdisziplinäres Zentrum für Public Health (IZPH), Universitätsklinikum Erlangen
- Deborah Marshall
- Health Research Innovation Centre, Cumming School of Medicine, University of Calgary
- Ulf Persson
- The Swedish Institute for Health Economics (IHE)
- Maarten Postma
- Department of Pharmacy, University of Groningen
- Steven Simoens
- KU Leuven Department of Pharmaceutical and Pharmacological Sciences
- Oriol de Solà Morales
- Institut Investigació Sanitaria Pere Virgili (IISPV)
- Keith Tolley
- Tolley Health Economics Ltd
- Mondher Toumi
- UFR d’Odontologie, University Claude Bernard Lyon I
- Harry Telser
- Polynomics AG
- James R Bonham
- Sheffield Children’s NHS Foundation Trust
- Helmut Hintner
- EB House Austria
- Anja Diem
- EB House Austria
- Martin Laimer
- EB House Austria
- Réjean Hébert
- Department of Health Evaluation, Management and Policy, School of Public Health, Université de Montréal
- Nabarun Dasgupta
- Epidemico, Inc.
- Carrie E. Pierce
- Epidemico, Inc.
- Melissa Jordan
- Epidemico, Inc.
- Barbara Bori
- Novartis Pharma AG
- Mohanad Fors
- Novartis Pharma AG
- Emilie Prazakova
- Novartis Pharma AG
- Simon Day
- Clinical Trials Consulting & Training Limited
- Thomas J. Croce
- Head of Global Patient Advocacy, Shire plc
- Jonas Fransson
- Sobi – Swedish Orphan Biovitrum AB (publ.)
- Philip Wood
- Sobi – Swedish Orphan Biovitrum AB (publ.)
- Anne-Grethe Lauridsen
- European Gaucher Alliance (EGA)
- Joanne Higgs
- European Gaucher Alliance (EGA)
- Vesna Stojmirova Aleksovska
- European Gaucher Alliance (EGA)
- Christina Olsen
- Ceratium Ltd
- Ritchie Head
- Ceratium Ltd
- Antonio Asero
- SIFI SpA
- Vincenzo Papa
- SIFI SpA
- Christa van Kan
- PSR Group B.V.
- Loic Favennec
- University of Rouen
- Silvana Venturella
- RTC
- Michela Salvador
- RTC
- Alan Krol
- Moorfields Pharmaceuticals
- Stephanie J. Nielsen
- Rare Diseases Denmark
- Birthe B. Holm
- Rare Diseases Denmark
- Daniel Lewi
- The Cure & Action for Tay-Sachs (CATS) Foundation
- Patricia Durão
- The Cure & Action for Tay-Sachs (CATS) Foundation
- Heather Band
- Batten Disease Family Association (BDFA), The Old Library
- Andrea West
- Batten Disease Family Association (BDFA), The Old Library
- Marinda J. A. Hammann
- Patient Organisation for Metabolic Diseases (VKS)
- Marije C. Effing-Boele
- Patient Organisation for Metabolic Diseases (VKS)
- Hanka K. Dekker
- Patient Organisation for Metabolic Diseases (VKS)
- Amy Hunter
- Genetic Alliance UK
- Amy Simpson
- Genetic Alliance UK
- Gumei Liu
- Office of Orphan Products Development, Office of Special Medical Programs, U.S. Food and Drug Administration
- Katherine Needleman
- Office of Orphan Products Development, Office of Special Medical Programs, U.S. Food and Drug Administration
- Debra Lewis
- Office of Orphan Products Development, Office of Special Medical Programs, U.S. Food and Drug Administration
- Gayatri Rao
- Office of Orphan Products Development, Office of Special Medical Programs, U.S. Food and Drug Administration
- Amy Simpson
- Genetic Alliance UK
- Amy Hunter
- Genetic Alliance UK
- Martin J. Whitaker
- University of Sheffield
- Raquel Castro
- European Organisation for Rare Diseases – EURORDIS
- DOI
- https://doi.org/10.1186/s13023-016-0515-y
- Journal volume & issue
-
Vol. 11,
no. S1
pp. 1 – 9
Abstract
Table of contents O1 The European Social Preferences Measurement (ESPM) study project: social cost value analysis, budget impact, commercial life cycle revenue management, and the economics of biopharmaceutical Research & Development (R&D) Michael Schlander, Søren Holm, Erik Nord, Jeff Richardson, Silvio Garattini, Peter Kolominsky-Rabas, Deborah Marshall, Ulf Persson, Maarten Postma, Steven Simoens, Oriol de Solà Morales, Keith Tolley, Mondher Toumi, Harry Telser O2 Newborn Screening: the potential and the challenges James R Bonham O3 Untreatable disease outcomes - how would we measure them? Helmut Hintner, Anja Diem, Martin Laimer O4 Taking Integrated Care Forward: Experiences from Canada to inspire service provision for people living with rare disease in Europe Réjean Hébert O5 Listening to the patient’s voice: social media listening for safety and benefits in rare diseases Nabarun Dasgupta, Carrie E. Pierce, Melissa Jordan O6 Via Opta: Mobile apps making visually impaired patients’ lives easier Barbara Bori, Mohanad Fors, Emilie Prazakova O7 A report of the IRDiRC “Small Population Clinical Trial” Task Force Simon Day O8 HAE patient identification and diagnosis: An innovative, ‘game changing’ collaboration Thomas J. Croce Jr. O9 Co-creating with the community: primary packaging & administration for people with haemophilia Jonas Fransson, Philip Wood O10 Go with Gaucher, taking forward the next generation. How to involve young people to create a new generation of patient advocates Anne-Grethe Lauridsen, Joanne Higgs, Vesna Stojmirova Aleksovska P1 ODAK – Orphan Drug for Acanthamoeba Keratitis Christina Olsen, Ritchie Head, Antonio Asero, Vincenzo Papa, Christa van Kan, Loic Favennec, Silvana Venturella, Michela Salvador, Alan Krol P5 Rare Navigators help people living with rare diseases to manage the social – and healthcare systems Stephanie J. Nielsen, Birthe B. Holm P6 The eAcademy for Tay-Sachs & Sandhoff disease app Daniel Lewi, Patricia Durão P10 The role of a patient organisation in driving the research agenda in a rare disease Heather Band, Andrea West P13 Expertise for rare diseases mapped Marinda J.A. Hammann, Marije C. Effing-Boele, Hanka K. Dekker P14 The hidden costs of rare diseases: a feasibility study Amy Hunter, Amy Simpson P15 FDA’s new natural history grant program: support to build a solid foundation for development of products for rare diseases Gumei Liu, Katherine Needleman, Debra Lewis, Gayatri Rao P17 Understanding the wider impact of adrenal insufficiency: patient organisation involvement in the TAIN project Amy Simpson, Amy Hunter, Martin J Whitaker P20 Bridging the gaps between medical and social care for people living with a rare disease Raquel Castro
Keywords
- Adrenal Insufficiency
- Epidermolysis Bullosa
- Patient Organisation
- Natural History Study
- Acanthamoeba Keratitis